Medical Devices

New AI voice agents promise to capture millions in lost revenue for med spas by working after hours. Is this the future of the aesthetic care market?

The private capital market leader's latest user-voted award reveals a major trend: authentic customer feedback is the new currency in high-stakes investing.

A shocking 9,000% rise in senior overdose deaths sparks a new video initiative. But is education enough to combat a crisis hidden in plain sight?

Oak Hill Advisors' record fundraise underscores a major shift in corporate finance, as private credit becomes the go-to capital source for large-cap firms.

A regulatory filing reveals a key investor's move in the Avadel bidding war, exposing the intense M&A hunger driving the future of health tech.

Amid rising geopolitical tensions, new US rare earth price assessments offer critical transparency. What does this mean for manufacturing and national security?

A new class of AI-driven blood tests can detect lung cancer recurrence years before imaging, shaking up patient care and the multi-billion dollar diagnostics market.

A startup's legal victory protects its revolutionary wound care tech derived from the axolotl, paving the way for a new era in regenerative medicine.

KB Home's sixth consecutive corporate responsibility award offers a surprising blueprint for the healthcare sector. Can a homebuilder's ESG strategy pay off for pharma?

As quantum threats loom, SEALSQ's strategic entry into medical chips with post-quantum cryptography could redefine data security and the industry's supply chain.

Early results for INT230-6 show 50% fewer severe side effects, raising hopes for a treatment that could eliminate the toxic 'red devil' chemo.

Adagio Medical lands ex-Medtronic exec Sean Salmon. His mission: drive its novel cryoablation tech to disrupt the competitive cardiac arrhythmia market.

Polyrizon's novel hydrogel shows it can stick to nasal tissue longer without slowing drug delivery, a key innovation in the fight against opioid overdose.

The return of a critical antibiotic after 14 years via a new, ultra-fast FDA pathway signals a major shift in U.S. industrial and health policy.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

Biomerica's regulatory win in Egypt is more than a market entry; it's a strategic move to disrupt healthcare with low-cost, rapid diagnostic tools.

A new 24g wearable device promises clinic-grade laser therapy for just $99. Can its high-power science truly democratize healing, or is it just hype?

After a decade of failed trials, a new drug shows promise in treating resistant lung cancer by reawakening the immune system and halting its spread.

A breakthrough genetic therapy for ALS offers hope, but a split verdict from Canadian health agencies reveals the tough calculus of innovation versus cost.

Beyond its first-ever dividend, Covalon's true story is one of clinical innovation driving record sales, navigating market shifts, and funding global growth.